ZIOPHARM Oncology, Inc.
1180 Avenue of the Americas
19th Floor
New York
New York
10036
United States
Tel: 646-214-0700
Fax: 646-214-0711
Website: http://www.ziopharm.com/
343 articles about ZIOPHARM Oncology, Inc.
-
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
-
Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics
1/26/2022
Ziopharm Oncology, Inc. today highlighted recent operational and corporate updates.
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
11/8/2021
Ziopharm Oncology, Inc., announced financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021
11/1/2021
Ziopharm Oncology, Inc., announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets.
-
Less than a month after appointing a new chief executive officer, Ziopharm Oncology announced a restructure that has resulted in over 50% of its workforce being axed.
-
BioSpace Movers & Shakers: Sept. 3
9/3/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ziopharm Oncology to Participate in September 2021 Investor Conferences
9/1/2021
Ziopharm Oncology, Inc., announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences
-
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions
8/30/2021
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the appointment of Kevin S. Boyle, Sr. as its new Chief Executive Officer, effective today.
-
Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates
8/9/2021
Ziopharm Oncology, Inc., provided corporate updates for the second quarter of 2021, ended June 30, 2021.
-
Ziopharm Oncology to Participate in Upcoming Conferences - May 24, 2021
5/24/2021
Ziopharm Oncology, Inc., a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, announced that Company management will participate in two upcoming investor conferences
-
Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting
5/19/2021
Ziopharm Oncology, Inc., held its annual shareholders meeting and reinforced its plan and vision for the Company developed and endorsed by the Board and management team.
-
Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates
5/6/2021
Ziopharm Oncology, Inc., announced its financial results for the first quarter ended March 31, 2021 and provided additional corporate updates.
-
Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley ’21 Two-Day Live Virtual Educational Symposium
5/4/2021
Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event
-
Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021Annual shareholder meeting to be held on May 19, 2021
4/29/2021
Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021
-
Ziopharm Oncology Scientific Advisor Laurence J. N. Cooper, PhD, MD, Presented Today at Aldevron’s Virtual Breakthrough Speakers SeriesPresentation Highlights Ziopharm’s Suite of Cellular Therapy Technologies
4/28/2021
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, was the inaugural presenter at Aldevron’s Virtual Breakthrough Speaker Series.
-
Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
4/19/2021
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.
-
Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual MeetingAdds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers
4/7/2021
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be presenting a poster at the upcoming American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting.
-
Chimeric antigen receptor (CAR-T) therapy is one of the biggest cancer therapy breakthroughs of our time, but as with any precise science, there is still some fine-tuning to be done to overcome safety risks, limited payload capacity, and the prohibitive cost of manufacturing.
-
Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
2/25/2021
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial results for the fourth quarter and year ended December 31, 2020 and provided several additional corporate updates.